Literature DB >> 3718168

Neurologic abnormalities in schizophrenic patients and their families. I. Comparison of schizophrenic, bipolar, and substance abuse patients and normal controls.

B T Woods, D K Kinney, D Yurgelun-Todd.   

Abstract

The prevalence of neurologic abnormalities detectable on standard clinical examination by neurologists blind to diagnosis was compared for DSM-III-diagnosed, age- and sex-matched groups consisting of 24 schizophrenic (SCZ) patients, 24 patients with bipolar affective disorder (MDI) with history of psychosis, 24 patients hospitalized for alcohol or other drug abuse (D/A), and 24 normal volunteers (NL). The SCZ group had significantly more total abnormalities than the other three; both the MDI and D/A groups in turn had more total abnormalities than normal controls. After exclusion of findings due to medication or otherwise unrelated to the pathogenesis of psychiatric illness, only the SCZ-NL, SCZ-MDI, and D/A-NL differences remained significant. When neurologic abnormalities were further restricted to those indicating localized dysfunction of the corticospinal tracts, basal ganglia, or cerebellum, the only two persistent significant differences were between SCZ-NL and SCZ-MDI groups.

Entities:  

Mesh:

Year:  1986        PMID: 3718168     DOI: 10.1001/archpsyc.1986.01800070043006

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  12 in total

Review 1.  Endophenotypes in schizophrenia: a selective review.

Authors:  Allyssa J Allen; Mélina E Griss; Bradley S Folley; Keith A Hawkins; Godfrey D Pearlson
Journal:  Schizophr Res       Date:  2009-02-15       Impact factor: 4.939

Review 2.  Motor System Pathology in Psychosis.

Authors:  Sebastian Walther; Vijay A Mittal
Journal:  Curr Psychiatry Rep       Date:  2017-10-30       Impact factor: 5.285

3.  Neurological soft signs in schizophrenia: assessment and correlates.

Authors:  F Mohr; W Hubmann; R Cohen; W Bender; C Haslacher; S Hönicke; R Schlenker; C Wahlheim; P Werther
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

4.  Basal ganglia shape abnormalities in the unaffected siblings of schizophrenia patients.

Authors:  Daniel Mamah; Michael P Harms; Lei Wang; Deanna Barch; Paul Thompson; Jaeyun Kim; Michael I Miller; John G Csernansky
Journal:  Biol Psychiatry       Date:  2008-03-04       Impact factor: 13.382

5.  Prefrontal brain network connectivity indicates degree of both schizophrenia risk and cognitive dysfunction.

Authors:  Paul G Unschuld; Alison S Buchholz; Mark Varvaris; Peter C M van Zijl; Christopher A Ross; James J Pekar; Christoph Hock; John A Sweeney; Carol A Tamminga; Matcheri S Keshavan; Godfrey D Pearlson; Gunvant K Thaker; David J Schretlen
Journal:  Schizophr Bull       Date:  2013-06-18       Impact factor: 9.306

6.  Neurological abnormalities among offspring of persons with schizophrenia: relation to premorbid psychopathology.

Authors:  Konasale M Prasad; Richard Sanders; John Sweeney; Debra Montrose; Vaibhav Diwadkar; Diana Dworakowski; Jean Miewald; Matcheri Keshavan
Journal:  Schizophr Res       Date:  2008-12-23       Impact factor: 4.939

7.  A family history study of schizophrenia spectrum disorders suggests new candidate genes in schizophrenia and autism.

Authors:  A B Goodman
Journal:  Psychiatr Q       Date:  1994

8.  Neurological soft signs in schizophrenia - The past, the present and the future.

Authors:  Shivarama Varambally; Ganesan Venkatasubramanian; Bangalore N Gangadhar
Journal:  Indian J Psychiatry       Date:  2012-01       Impact factor: 1.759

9.  The presence of neurological soft signs along the psychosis proneness continuum.

Authors:  Emma Barkus; John Stirling; Richard Hopkins; Shôn Lewis
Journal:  Schizophr Bull       Date:  2006-01-11       Impact factor: 9.306

10.  Neurological Soft Signs (NSS) in Census-Based, Decade-Adjusted Healthy Adults, 20 to >70 Years of Age.

Authors:  Silke Bachmann; Michaela Beck; Dai-Hua Tsai; Friederike Haupt
Journal:  Front Psychiatry       Date:  2021-06-24       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.